However, we found that MLKL loss upregulates neither DR5 nor DR4, another TRAIL receptor [2], in CRC cells neither before nor after HHT treatment (Supplementary Fig. 2B, C). The gene discussed is MLKL; the disease is colorectal carcinoma.